We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




RNA Sequencing Identifies Novel Cell Class Linked to Rheumatoid Arthritis Flares

By LabMedica International staff writers
Posted on 28 Jul 2020
A novel class of blood cells has been identified, which may serve as a biomarker able to predict the imminent occurrence of an episodic “flare” in patients with rheumatoid arthritis.

Rheumatoid arthritis, like many inflammatory diseases, is characterized by episodes of quiescence and exacerbation (flares). More...
The molecular events leading to flares are unknown.

In order to search for molecular markers able to predict the onset of a flare, investigators at Rockefeller University (New York, NY, USA) established a clinical and technical protocol for repeated home collection of blood in patients with rheumatoid arthritis to allow for longitudinal RNA sequencing (RNA-seq).

Following this protocol, specimens were obtained from 364 time points during eight flares over a period of four years in one patient, as well as from 235 time points during flares in three additional patients. Transcripts were found that were differentially expressed before flares, and these were compared with data from synovial single-cell RNA-seq. Flow cytometry and sorted-blood-cell RNA-seq in additional patients were used to validate the findings.

Results revealed consistent changes in blood transcriptional profiles one to two weeks before a rheumatoid arthritis flare. B-cell activation was followed by expansion of a novel class of circulating PRIME (CD45−CD31−PDPN+ preinflammatory mesenchymal) cells in the blood. These cells shared features of inflammatory synovial fibroblasts. Levels of circulating PRIME cells decreased during flares in all four patients, and flow cytometry and sorted-cell RNA-seq confirmed the presence of PRIME cells in 19 additional patients with rheumatoid arthritis.

"PRIME cells are one thing you might want to target to arrest the flare before it happens," said senior author Dr. Robert B. Darnell, professor of cancer biology at Rockefeller University. "That is the ideal of medical science - to know enough about a disease that you can put your finger on what is about to make someone sick."

The rheumatoid arthritis paper was published in the July 16, 2020, online edition of the New England Journal of Medicine.

Related Links:
Rockefeller University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.